首页> 外文OA文献 >European and Developing Countries Clinical Trials Partnership (EDCTP): The Path Towards a True Partnership.
【2h】

European and Developing Countries Clinical Trials Partnership (EDCTP): The Path Towards a True Partnership.

机译:欧洲和发展中国家临床试验伙伴关系(EDCTP):通向真正伙伴关系的道路。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

European and Developing Countries Clinical Trials Partnership (EDCTP) was founded in 2003 by the European Parliament and Council. It is a partnership of 14 European Union (EU) member states, Norway, Switzerland, and Developing Countries, formed to fund acceleration of new clinical trial interventions to fight the human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), malaria and tuberculosis (TB) in the sub-Saharan African region. EDCTP seeks to be synergistic with other funding bodies supporting research on these diseases. EDCTP promotes collaborative research supported by multiple funding agencies and harnesses networking expertise across different African and European countries. EDCTP is different from other similar initiatives. The organisation of EDCTP blends important aspects of partnership that includes ownership, sustainability and responds to demand-driven research. The Developing Countries Coordinating Committee (DCCC); a team of independent scientists and representatives of regional health bodies from sub-Saharan Africa provides advice to the partnership. Thus EDCTP reflects a true partnership and the active involvement and contribution of these African scientists ensures joint ownership of the EDCTP programme with European counterparts. The following have been the major achievements of the EDCTP initiative since its formation in 2003; i) increase in the number of participating African countries from two to 26 in 2008 ii) the cumulative amount of funds spent on EDCTP projects has reached 150 m euros, iii) the cumulative number of clinical trials approved has reached 40 and iv) there has been a significant increase number and diversity in capacity building activities. While we recognise that EDCTP faced enormous challenges in its first few years of existence, the strong involvement of African scientists and its new initiatives such as unconditional funding to regional networks of excellence in sub-Saharan Africa is envisaged to lead to a sustainable programme. Current data shows that the number of projects supported by EDCTP is increasing. DCCC proposes that this success story of true partnership should be used as model by partners involved in the fight against other infectious diseases of public health importance in the region.
机译:欧洲和发展中国家临床试验合作伙伴关系(EDCTP)由欧洲议会和理事会于2003年成立。它是由14个欧盟(EU)成员国,挪威,瑞士和发展中国家组成的伙伴关系,旨在为加速新的临床试验干预措施提供资金,以抗击人类免疫缺陷病毒和获得性免疫缺陷综合症(HIV / AIDS),疟疾和撒哈拉以南非洲地区的结核病。 EDCTP寻求与支持这些疾病研究的其他资助机构协同作用。 EDCTP促进由多个资助机构支持的合作研究,并利用非洲和欧洲不同国家/地区的网络专业知识。 EDCTP与其他类似计划不同。 EDCTP的组织融合了伙伴关系的重要方面,包括所有权,可持续性并响应需求驱动的研究。发展中国家协调委员会(DCCC);一个独立的科学家团队和一个来自撒哈拉以南非洲地区卫生机构的代表为该伙伴关系提供了建议。因此,EDCTP反映了真正的伙伴关系,这些非洲科学家的积极参与和贡献确保了与欧洲同行共同拥有EDCTP计划。自EDCTP计划于2003年成立以来,以下是其主要成就; i)参与的非洲国家数量从2008年的两个增加到2008年的26个)ii)用于EDCTP项目的累计资金已达1.5亿欧元,iii)批准的临床试验的累计数量已达40个,并且iv)有能力建设活动的数量和多样性显着增加。尽管我们认识到EDCTP在成立的最初几年中面临着巨大挑战,但可以预见非洲科学家的大力参与和其新举措,例如无条件资助撒哈拉以南非洲区域卓越网络,将导致一项可持续方案。当前数据显示,EDCTP支持的项目数量正在增加。 DCCC提出,真正的伙伴关系的成功故事应被参与该地区与其他具有重要公共卫生意义的传染病斗争的伙伴作为典范。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号